Eli Lilly has launched its obesity treatment, Mounjaro, in India, making a significant play in one of the world’s largest pharmaceutical markets.
The company confirmed the rollout of Mounjaro—a GLP-1-based obesity medication—in India earlier this week. This strategic move positions Eli Lilly ahead of its primary competitor, Novo Nordisk, maker of the popular weight-loss drug Wegovy, in accessing India’s massive market of approximately 1.4 billion people.
After receiving approval from India’s drug regulatory authorities, Mounjaro will be administered as a once-weekly injection. Pricing in India is set at 4,375 rupees ($50.67) for a 5mg dose vial and 3,500 rupees ($40.54) for a 2.5mg vial. For patients receiving a standard weekly dose of 5mg, that equates to roughly $200 monthly.
Mounjaro’s active ingredient, tirzepatide, belongs to a class of medications known as GLP-1 receptor agonists—the same class as Wegovy. Tirzepatide is marketed under the Mounjaro brand in the U.K. and Europe for diabetes and obesity treatment. In the U.S., Eli Lilly sells Zepbound specifically for obesity treatment.
Most Commented